NASDAQ
European Biotech Acquisition Corp. (EBAC) has a free cash flow growth of 327.94% as of Friday, May 29, 2026. This represents a 841.15% increase compared to its 12-month average of -44.25%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.